David Shaw’s Connect Biopharma Holdings CNTB Stock Holding History

David Shaw’s Portfolio CNTB Stock Details CNTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-13,750	Closed	-$12K	–	5232
2022 Q2	$12K	Buy	+13,750	New	+$20.3K	﹤0.01%	5107

Other funds holding CNTB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

David Shaw's CNTB Position: Q3 2022 in Review

David Shaw sold out of Connect Biopharma Holdings (CNTB) in Q3 2022, closing a stake of 13,750 shares — an estimated $12K sold.

David Shaw first reported a position in CNTB in Q2 2022 and held it in 1 quarter. The position peaked at $12K in Q2 2022. 25 funds tracked by Wall St. Rank hold CNTB as of Q3 2022.

David Shaw reported no remaining Connect Biopharma Holdings position as of Q3 2022 after selling out during the quarter.
David Shaw sold 13,750 Connect Biopharma Holdings shares in Q3 2022, an estimated $12K.
David Shaw first reported a position in Connect Biopharma Holdings in Q2 2022 and held it in 1 quarter.
David Shaw's Connect Biopharma Holdings position peaked at $12K in Q2 2022.
25 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.